Coverage-gated living condition brief

Chronic Kidney Disease peptide evidence brief

A cited Chronic Kidney Disease peptide evidence brief across 23 exact-label ClinicalTrials.gov records, 9 connected profiles, and 9 registry-update years. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.

Registry records

23 selected records.

Connected peptides

9 profiles.

Registry update years

2012–2026 in selected records.

Direct collection answer · published August 17, 2026

What peptide evidence does PeptideScanner carry for Chronic Kidney Disease?

PeptideScanner’s selected collection contains 23 retained ClinicalTrials.gov records carrying the exact condition label “Chronic Kidney Disease,” connected to 9 peptide profiles across 9 registry-update years.

That answer describes this collection and the exact cited registry observations below. It is not a conclusion about whether any peptide treats Chronic Kidney Disease, and it is not a safety or efficacy assessment.

Indication intelligence

Selected evidence landscape

Trial phases5

Phase labels copied from the retained ClinicalTrials.gov versions.

Registry statuses4

Overall statuses at each retained observation, not necessarily current today.

Across the connected peptide profiles, PeptideScanner also carries 271 selected PubMed records and 42 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Chronic Kidney Disease unless their own cited source says so.

Related profile context

Literature connected through these peptide profiles

All literature facets →

This is a bounded sample of up to six PubMed bibliography records connected through peptide profiles on this hub, not the total profile literature count above. They are not condition-matched records, and their presence does not establish that they concern Chronic Kidney Disease.

Peginesatide · source record 2026-11-09

Peginesatide acetate, axitinib, and pertuzumab.

PubMed lists PMID 23023854 in Journal of the American Pharmacists Association : JAPhA as Journal Article, Review, with publication-date metadata of 2012 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Etelcalcetide · source record 2026-10-31

Long-term use of etelcalcetide for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis for end-stage renal failure: a real-life retrospective observational study.

PubMed lists PMID 36790677 in International urology and nephrology as Observational Study, Journal Article, with publication-date metadata of 2023-02-15 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Daptomycin · source record 2026-11-09

Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial.

PubMed lists PMID 32725216 in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Equivalence Trial, with publication-date metadata of 2021-05-04 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

MK-677 · source record 2026-01-27

LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report.

PubMed lists PMID 36303408 in Experimental physiology as Case Reports, Research Support, Non-U.S. Gov't, Journal Article, with publication-date metadata of 2022-11-16 (day precision). PeptideScanner associated the retained record with the identity slug mk-677. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Orforglipron · source record 2026-11-09

Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.

PubMed lists PMID 41994902 in Diabetes, obesity & metabolism as Clinical Trial, Phase I, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Collection change ledger

Recently changed records on this condition hub

All recent changes →

These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.

Record added

ClinicalTrials.gov record NCT00097747

PeptideScanner retained ClinicalTrials.gov record NCT00097747 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide.

PeptideScanner change date
November 16, 2026
Cited source date
December 21, 2012
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00228436

PeptideScanner retained ClinicalTrials.gov record NCT00228436 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide.

PeptideScanner change date
November 16, 2026
Cited source date
December 21, 2012
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00228449

PeptideScanner retained ClinicalTrials.gov record NCT00228449 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide.

PeptideScanner change date
November 16, 2026
Cited source date
December 21, 2012
Evidence lane
Clinical trials

Exact-record source chronology

Chronic Kidney Disease registry timeline

All trial facets →

Years come from the last-update date on each retained ClinicalTrials.gov observation. They show source chronology, not when PeptideScanner added the record and not a continuous monitoring guarantee.

2026

7 records

2024

1 record

2021

1 record

2019

2 records

2018

1 record

2017

1 record

2016

1 record

2013

4 records

2012

5 records
What this brief cannot answer